Prove cliniche Nct

Summary
EudraCT Number:2004-005123-18
Sponsor's Protocol Code Number:104020
National Competent Authority:Finland - Fimea
Clinical Trial Type:EEA CTA
Trial Status:Completed
Date on which this record was first entered in the EudraCT database:2005-02-22
Trial results View results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL
A. Protocol Information
A.1Member State ConcernedFinland - Fimea
A.2EudraCT number2004-005123-18
A.3Full title of the trial
A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), when given as a two-dose schedule to healthy children in their second year of life.
A.3.2Name or abbreviated title of the trial where available
MeMuRu-OKA 043
A.4.1Sponsor's protocol code number104020
A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorGlaxoSmithKline
B.1.3.4CountryFinland
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing support
B.4.2Country
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisation
B.5.2Functional name of contact point
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namePriorix-Tetra
D.3.2Product code MeMuRu-OKA
D.3.4Pharmaceutical form Powder and solvent for solution for injection
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated mumps vaccine, Jeryl Lynn strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number4.4 log10 CCID50
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated measles vaccine, Schwarz strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.0 log10 CCID50
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated rubella vaccine, RA 27/3 strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.0 log10 CCID50
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated varicella vaccine, OKA strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.3 log10 PFU
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
D.3.11.7Plasma derived medicinal product Information not present in EudraCT
D.3.11.8Extractive medicinal product Information not present in EudraCT
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 2
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
D.2.1.1.1Trade name Varilrix Injektiokuiva-aine ja liuotin
D.2.1.1.2Name of the Marketing Authorisation holderGlaxoSmithKline Biologicals s.a.
D.2.1.2Country which granted the Marketing AuthorisationFinland
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product nameVarilrix
D.3.2Product code OKA
D.3.4Pharmaceutical form Powder and solvent for solution for injection
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated varicella vaccine, OKA strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.3 log10 PFU
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
D.3.11.7Plasma derived medicinal product Information not present in EudraCT
D.3.11.8Extractive medicinal product Information not present in EudraCT
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 3
D.1.2 and D.1.3IMP RoleComparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
D.2.1.1.1Trade name Priorix injektiokuiva-aine ja liuotin
D.2.1.1.2Name of the Marketing Authorisation holderGlaxoSmithKline Biologicals s.a.
D.2.1.2Country which granted the Marketing AuthorisationFinland
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namePriorix
D.3.2Product code MeMuRu
D.3.4Pharmaceutical form Powder and solvent for solution for injection
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPIntramuscular use
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated mumps vaccine, Jeryl Lynn strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.7 log10 CCID50
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated measles vaccine, Schwarz strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.0 log10 CCID50
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNLive attenuated rubella vaccine, RA 27/3 strain
D.3.10 Strength
D.3.10.2Concentration typenot less then
D.3.10.3Concentration number3.0 log10 CCID50
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
D.3.11.7Plasma derived medicinal product Information not present in EudraCT
D.3.11.8Extractive medicinal product Information not present in EudraCT
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.
MedDRA Classification
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
 To establish an observed seroconversion rate for mumps of at least 90% for each lot after the first dose by neutralization assay.
E.2.2Secondary objectives of the trial
 To assess immunogenicity of study vaccines in terms of mumps seroconversion rate post dose 1 by neutralization assay (sequential analysis):
(1) To demonstrate LL of 95% CI mumps SC-rate is at least 90% after the first dose of MeMuRu-OKA Lot A-FRESH.
(2) To demonstrate LL of 95% CI mumps SC-rate is at least 90% after the first dose of MeMuRu-OKA Lot A-AGED.
(3) To demonstrate LL of 95% CI mumps SC-rate is at least 90% after the first dose of MeMuRu-OKA Lot B-AGED.
 To assess immunogenicity:
- mumps SC-rate post dose 1 (ELISA)
- measles-rubella-varicella SC-rates post dose 1.
- antibody titres to each vaccine component post dose 1.
- SC-rates and antibody titres to each vaccine component post dose 2.
 To assess reactogenicity & safety after each dose.
E.2.3Trial contains a sub-study Information not present in EudraCT
E.3Principal inclusion criteria
 Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
 A male or female subjects between 11 to 21 months of age at the time of the first vaccination.
 Written informed consent obtained from the parent or guardian of the subject.
 Free of obvious health problems as established by medical history and clinical examination before entering into the study.
E.4Principal exclusion criteria
 Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
 Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent,  0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
 Planned administration/ administration of a vaccine not foreseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12).
 Previous vaccination against measles, mumps, rubella and/or varicella.
 History of measles, mumps, rubella and/or varicella/zoster diseases.
 Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial.
 Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
 A family history of congenital or hereditary immunodeficiency.
 History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
 Major congenital defects or serious chronic illness.
 History of any neurologic disorders or seizures.
 Residence in the same household as the following persons:
– New-born infants (0-4 weeks of age).
– Pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox.
– Persons with known immunodeficiency.
 Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature <37.5°C / Rectal temperature <38.0°C.
 Rectal temperature 38.0°C or axillary temperature 37.5°C at the time of vaccination.
 Administration of immunoglobulins and/or any blood products within the six months before entering the study or planned administration during the study period.
E.5 End points
E.5.1Primary end point(s)
 Mumps seroconversion rate after the first dose by neutralisation assay.
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis Yes
E.6.3Therapy No
E.6.4Safety Yes
E.6.5Efficacy No
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic Information not present in EudraCT
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others Yes
E.6.13.1Other scope of the trial description
immunogenicity
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) Yes
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open Yes
E.8.1.3Single blind No
E.8.1.4Double blind Yes
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo No
E.8.2.3Other Yes
E.8.2.3.1Comparator description
Priorix and Varilrix vaccines
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.5The trial involves multiple Member States Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA Yes
E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
E.8.7Trial has a data monitoring committee Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
Conclusion/last visit: Visit 3/Week 12
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years0
E.8.9.1In the Member State concerned months7
E.8.9.1In the Member State concerned days
E.8.9.2In all countries concerned by the trial years0
E.8.9.2In all countries concerned by the trial months7
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) Yes
F.1.1.5Children (2-11years) No
F.1.1.6Adolescents (12-17 years) No
F.1.2Adults (18-64 years) No
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers Yes
F.3.2Patients No
F.3.3Specific vulnerable populations Information not present in EudraCT
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception Information not present in EudraCT
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally Yes
F.3.3.6.1Details of subjects incapable of giving consent
Subjects below the legal age of consent (<2years of age)
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state250
F.4.2 For a multinational trial
F.4.2.1In the EEA 1182
F.4.2.2In the whole clinical trial 1442
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
Subjects who demonstrated a sub-optimal response to vaccination will be offered Priorix and/or Varilrix vaccines.
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2005-04-15
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2005-03-30
P. End of Trial
P.End of Trial StatusCompleted
P.Date of the global end of the trial2005-11-22

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi